Actionable news
All posts from Actionable news
Actionable news in PRGO: PERRIGO COMPANY PLC,

Pharma Names Under Pressure Amid Perrigo Warning

Invest with Confidence. Are you a financial professional? Stay on top of your portfolio with Benzinga Pro's real-time newsfeed and alerts and never miss a headline again.
Don't miss the chance to try it FREE today.

Shares of Perrigo Company plc PRGO 15.41% plunged more than 15 percent on Monday and hit a new 52-week low after the company appointed John T. Hendrickson as CEO and provided preliminary first quarter results in addition to full year 2016 guidance.

Henrdickson was named as CEO following the retirement of Joseph Papa, who accepted the CEO title at Valeant Pharmaceuticals Intl Inc VRX 0.03%.

Perrigo's first quarter preliminary guidance consisted of an earnings per share range of $1.71 to $1.77 on sales of $1.33 billion to $1.35 billion. Wall Street analysts were expecting the company to earn $1.89 per share on revenue of $1.4 billion.

Looking forward to the full fiscal year, Perrigo cut its earnings per share guidance range from $9.50 to $10.10 per share to a new range of $8.20 to $8.60 per share.

Perrigo's disappointing outlook resulted in a sell-off in other pharmaceutical names.

Shares of Allergan plc AGN 2.2% were trading lower by around 2 percent, while shares of Teva Pharmaceuticals Industries Ltd TEVA 1.72% lost around 1.5 percent.

Shares of both Merck & Co., Inc. MRK 1.14% and AbbVie Inc ABBV 0.98% were lower by more than 1 percent each, while Pfizer Inc. PFE 0.64% saw its shares shed around 0.60 percent.

© 2016 Benzinga does not provide investment advice. All rights reserved.